Meeting
2016 ASCO Annual Meeting
Radiologic progression types are treatment specific: An exploratory analysis of a phase 3 study of bevacizumab plus radiotherapy plus temozolomide for patients with newly diagnosed glioblastoma (AVAglio).
Authors
Martha Nowosielski
Medical University Innsbruck, Innsbruck, Austria
Martha Nowosielski , Olivier L. Chinot , Alexander Radbruch , Guenther Stockhammer , Josep Garcia , Cedric Revil , Ryo Nishikawa , Warren P. Mason , Roger Henriksson , Frank Saran , Martin Bendszus , Lauren E. Abrey , Timothy Francis Cloughesy , Wolfgang Wick
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT00943826
Citation
J Clin Oncol 34, 2016 (suppl; abstr 2048)
DOI
10.1200/JCO.2016.34.15_suppl.2048
Abstract #
2048
Poster Bd #
235
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Patterns of tumor progression in a phase 3 study of bevacizumab (Bv) plus radiotherapy (RT) plus temozolomide (T) for newly diagnosed glioblastoma (GB).
First Author: Wolfgang Wick
Poster
2013 ASCO Annual Meeting
Biomarker (BM) evaluations in the phase III AVAglio study of bevacizumab (Bv) plus standard radiotherapy (RT) and temozolomide (T) for newly diagnosed glioblastoma (GBM).
First Author: Ryo Nishikawa
Poster
2020 ASCO Virtual Scientific Program
Phase III TRIDENT trial: Radiation and temozolomide +/- tumor treating fields in newly diagnosed glioblastoma.
First Author: Wenyin Shi
Poster
2014 ASCO Annual Meeting
Survival and quality of life in the randomized, multicenter GLARIUS trial investigating bevacizumab/irinotecan versus standard temozolomide in newly diagnosed, MGMT-non-methylated glioblastoma patients.
First Author: Ulrich Herrlinger